Species | Human |
Antigen | EphB2 |
Synonyms | CAPB, Cek5, Drt, DRTEphB2, EC 2.7.10, EC 2.7.10.1, EK5, elk-related tyrosine kinase, EPH receptor B2, eph tyrosine kinase 3, EphB2, EPH-like kinase 5, ephrin type-B receptor 2, EPHT3MGC87492, EPTH3, Erk, ERKHek5, Hek5, Nuk, PCBC, protein-tyrosine kinase HEK5, Qek2, Renal carcinoma antigen NY-REN-47, Sek3, Tyro5, Tyrosine-protein kinase receptor EPH-3, Tyrosine-protein kinase TYRO5 |
Accession | P29323 |
Amino Acid Sequence | Val19-Leu543, with C-terminal 10*His
VEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPINSRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDSGGREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLAHTQYTFEIQAVNGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVDSITLSWSQPDQPNGVILDYELQYYEKELSEYNATAIKSPTNTVTVQGLKAGAIYVFQVRARTVAGYGRYSGKMYFQTMTEAEYQTSIQEKLPLGGGSGGGSHHHHHHHHHH |
Expression System | HEK293 |
Molecular Weight | 70-80kDa |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
|
Reference | 1. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O., Tuzmen S., Weaver D., Robbins C., Moses T., Mousses S.
2. A mutation of the human EPHB2 gene leads to a major platelet functional defect. Berrou E., Soukaseum C., Favier R., Adam F., Elaib Z., Kauskot A., Bordet J.C., Ballerini P., Loyau S., Bryckaert M. |